Tamar Thompson, MS

BOARD MEMBER
Chief Strategy Officer, CXO, COO, Public Company Director

VP, Head of Patient Experience & Insights, Alexion Pharmaceuticals /
AstraZeneca Rare Disease

With more than three decades of leadership across the life sciences sector, Ms. Thompson brings deep expertise in corporate affairs, policy strategy, and enterprise transformation, particularly within high-growth and rare disease markets.

Ms. Thompson currently serves as VP, Head of Patient Experience & Insights at Alexion Pharmaceuticals, part of AstraZeneca. In this role, she leads enterprise efforts to elevate patient-centered strategy, integrating insights, advocacy, and innovation to improve outcomes for rare disease patients worldwide. Previously at Alexion, she led Global Corporate Affairs and U.S. Government Affairs and Policy, where she built and scaled integrated functions spanning communications, advocacy, and stakeholder engagement.

In addition, Ms. Thompson currently serves as an Independent Director at Avidity Biosciences and Catalyst Pharmaceuticals, where she provides strategic guidance on governance, risk management, executive performance, and long-term growth.

Earlier in her career, Ms. Thompson held senior leadership roles at Bristol Myers Squibb and ADVI Health, where she led policy strategy, secured critical reimbursement and access wins, and supported the adoption of innovative therapies. Her policy leadership also contributed to the passage of the Orphan Cures Act, helping preserve incentives for rare disease innovation.

She previously served as Board Director and Chair at HealthyWomen, as Board Chairman of MassBio, where she continues to serve on the Executive Committee, and as a member of the Leadership Council of the Mass General Schwartz Center for Compassionate Healthcare, supporting efforts to advance compassionate, patient-focused care.